Matinas Biopharma (MTNB) Stock Price, News & Analysis

Company Overview

Matinas Biopharma Inc. is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections. Unlike standard intravenous amphotericin B, MAT2203 is formulated for once‐daily oral dosing and is intended to offer a lower toxicity profile. Matinas is also advancing MAT9001, an intravenous formulation of omega‐3 fatty acids for the management of severe hypertriglyceridemia, and MAT2501, an intravenous lipid‐based formulation of gentamicin for multidrug‐resistant bacterial infections.

Founded in 2012 and headquartered in Bedminster, New Jersey, Matinas Biopharma has designed its pipeline to address high‐unmet‐need areas in infectious disease and metabolic disorders. The company’s development programs have been conducted under U.S. Food and Drug Administration guidance, with clinical trials carried out at sites across North America. Matinas pursues strategic collaborations and licensing partnerships to broaden the application of its LNS technology to vaccines, oncology agents and biologics.

Matinas Biopharma completed its initial public offering in 2020 and trades on the New York Stock Exchange under the ticker symbol MTNB. The company’s management team brings together expertise in pharmaceutical R&D, regulatory affairs and commercial development, with the goal of translating its lipid‐delivery platform into safe, effective and convenient therapies for patients worldwide.

Key Stats

• Today's Range: $0.58 to $0.67
• 50-Day Range: $0.49 to $0.68
• 52-Week Range: $0.48 to $3.09
• Volume: 96,067 shs
• Average Volume: 98,054 shs
• Market Capitalization: $4.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Matinas Biopharma Stock Analysis - MarketRank™

Matinas Biopharma scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Matinas Biopharma.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Matinas Biopharma is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Matinas Biopharma is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Matinas Biopharma has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.07% of the float of Matinas Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Matinas Biopharma has a short interest ratio ("days to cover") of 0.12, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Matinas Biopharma has recently increased by 26.35%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Matinas Biopharma does not currently pay a dividend.

Dividend Growth

Matinas Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Matinas Biopharma this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Matinas Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.60% of the stock of Matinas Biopharma is held by insiders.

Percentage Held by Institutions

11.77% of the stock of Matinas Biopharma is held by institutions.

Company Calendar

• Last Earnings: 5/08/2026
• Today: 5/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:MTNB
• Previous Symbol: NYSE:MTNB
• CIK: 1582554
• Web: N/A
• Phone: (908) 484-8805
• Fax: N/A
• Employees: 30
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): ($3.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.35 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -193.02%
• Return on Assets: -124.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.32
• Quick Ratio: 1.32

Sales & Book Value

• Annual Sales: $1.10 million
• Price / Sales: 3.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.47 per share
• Price / Book: 1.43

Miscellaneous

• Outstanding Shares: 6,410,000
• Free Float: 6,111,000
• Market Cap: $4.29 million
• Optionable: N/A
• Beta: 1.61